Indonesia Is Injecting $1.1 Billion Into BPJS Kesehatan as 52 Million Members Lapse on Premiums
- Indonesia will inject Rp20 trillion (about $1.1bn) into BPJS Kesehatan, the national health insurer, to cover its 2026 deficit, Finance Minister Suahasil Nazara said after a meeting with President Prabowo Subianto on 28 September 2026. The money arrives in two tranches of Rp10 trillion, in October and November, from existing 2026 budget funds.
- BPJS Kesehatan has collected Rp118 trillion in premiums this year against Rp132 trillion paid in benefits, leaving a cash-flow gap of about Rp14 trillion. The insurer covers some 285 million people, according to Reuters.
- The injection is separate from the roughly Rp47 trillion the state already spends subsidising premiums for 96.8 million lower-income citizens. President director Prihati Pujowaskito said about 52 million participants have lapsed on their monthly premiums, and the minister urged better collection and targeting.
- About a year ago the government set aside another Rp20 trillion to settle premium arrears, the Jakarta Globe reported at the time, alongside a planned rise in the national health insurance budget to Rp69 trillion for 2026.
Access read
The injection keeps hospital claims paid for two months. It does not change the arithmetic that created the gap.
- This is the second Rp20 trillion rescue in about a year. The first cleared premium arrears; this one covers claims. Repeated top-ups on this scale point to a structural shortfall rather than a one-off cash-flow problem.
- Collection is the core problem. Some 52 million lapsed members is about 18% of the 285 million covered, and premium income trails claims even with the state paying for 96.8 million people. The minister’s call to improve collection is the part of the announcement that decides whether the gap reopens next year.
- For drug makers, the payer’s cash sets the pace. In a single-payer system of this size, the insurer’s liquidity governs how fast hospitals are paid, and with it how much room there is for newer, higher-priced medicines in hospital budgets.